Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies

References

• Rijavec E, Biello F, Barletta G, Dellepiane C, Genova C. Novel approaches for the treatment of unresectable malignant pleural mesothelioma: a focus on immunotherapy and target therapy (Review). Mol Clin Oncol. 2022;16:89.
   PubMed Web of Science ®Google Scholar
• Tsao AS, Pass HI, Rimner A, Mansfield AS. New era for malignant pleural mesothelioma: updates on therapeutic options. J Clin Oncol off J Am Soc Clin Oncol. 2022;40:681–692. doi:10.1200/JCO.21.01567
   PubMed Web of Science ®Google Scholar
• Fennell DA, Dulloo S, Harber J. Immunotherapy approaches for malignant pleural mesothelioma. Nat Rev Clin Oncol. 2022;19:573–584. doi:10.1038/s41571-022-00649-7
   PubMed Web of Science ®Google Scholar
• Hu ZI, Ghafoor A, Sengupta M, Hassan R. Malignant mesothelioma: advances in immune checkpoint inhibitor and mesothelin-targeted therapies. Cancer. 2021;127:1010–1020. doi:10.1002/cncr.33433
   PubMed Web of Science ®Google Scholar
• Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, Phase 3 trial. Lancet Lond Engl. 2021;397:375–386. doi:10.1016/S0140-6736(20)32714-8
   PubMed Web of Science ®Google Scholar
• Briolay T, Petithomme T, Fouet M, et al. Delivery of cancer therapies by synthetic and bio-inspired nanovectors. Mol Cancer. 2021;20:55. doi:10.1186/s12943-021-01346-2
   PubMed Web of Science ®Google Scholar
• Arrieta Ó, Medina LA, Estrada-Lobato E, et al. First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer. 2012;106:1027–1032. doi:10.1038/bjc.2012.44
   PubMed Web of Science ®Google Scholar
• Arrieta O, Medina LA, Estrada-Lobato E, et al. High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with (99m)Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin. Cancer Chemother Pharmacol. 2014;74:211–215. doi:10.1007/s00280-014-2477-x
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Kato A, Hida Y, et al. Synergistic enhancement of cellular uptake with CD44-expressing malignant pleural mesothelioma by combining cationic liposome and hyaluronic acid-lipid conjugate. J Pharm Sci. 2019;108:3218–3224. doi:10.1016/j.xphs.2019.06.012
   PubMed Web of Science ®Google Scholar
• Hassan R, Thomas A, Alewine C, et al. Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol off J Am Soc Clin Oncol. 2016;34:4171–4179. doi:10.1200/JCO.2016.68.3672
   PubMed Web of Science ®Google Scholar
• Morello A, Sadelain M, Adusumilli PS. Mesothelin-Targeted CARs: driving T Cells to Solid Tumors. Cancer Discov. 2016;6:133–146. doi:10.1158/2159-8290.CD-15-0583
   PubMed Web of Science ®Google Scholar
• Weidemann S, Gagelmann P, Gorbokon N, et al. Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors. Biomedicines. 2021;9:397. doi:10.3390/biomedicines9040397
   PubMed Web of Science ®Google Scholar
• Klampatsa A, Dimou V, Albelda SM. Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opin Biol Ther. 2021;21:473–486. doi:10.1080/14712598.2021.1843628
   PubMed Web of Science ®Google Scholar
• Hagerty BL, Pegna GJ, Xu J, Tai C-H, Alewine C. Mesothelin-targeted recombinant immunotoxins for solid tumors. Biomolecules. 2020;10:973. doi:10.3390/biom10070973
   PubMed Web of Science ®Google Scholar
• Zhai X, Mao L, Wu M, Liu J, Yu S. Challenges of anti-mesothelin CAR-T-cell therapy. Cancers. 2023;15:1357. doi:10.3390/cancers15051357
   PubMed Web of Science ®Google Scholar
• Cao G, Cao W, Zhang J, et al. Mesothelin targeted nano-system enhanced chemodynamic therapy and tirapazamine chemotherapy via lactate depletion. Nano Res. 2023;(5):7108–7118. doi:10.1007/s12274-022-5301-7
   Web of Science ®Google Scholar
• Conte M, Frantellizzi V, Matto A, De Vincentis G. New insight and future perspective of mesothelin-targeted agents in nuclear medicine. Clin Transl Imaging. 2020;8:265–278. doi:10.1007/s40336-020-00379-9
   Web of Science ®Google Scholar
• Alfaleh MA, Howard CB, Sedliarou I, et al. Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models. PLoS One. 2017;12:e0186137. doi:10.1371/journal.pone.0186137
   PubMed Web of Science ®Google Scholar
• Deng L, Ke X, He Z, et al. A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer. Int J Nanomed. 2012;7:5053–5065. doi:10.2147/IJN.S34801
   PubMed Web of Science ®Google Scholar
• Tian H, Zhang T, Qin S, et al. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J Hematol Oncol. 2022;15:132.
   PubMed Web of Science ®Google Scholar
• Yao Y, Zhou Y, Liu L, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7. doi:10.3389/fmolb.2020.00193
   Web of Science ®Google Scholar
• Mauricio D, Harold J, Tymon-Rosario JR, Zeybek B, Santin AD. Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer. Expert Opin Biol Ther. 2021;21:1087–1096. doi:10.1080/14712598.2021.1869210
   PubMed Web of Science ®Google Scholar
• Shen J, Sun X, Zhou J. Insights into the role of mesothelin as a diagnostic and therapeutic target in ovarian carcinoma. Front Oncol. 2020;10:1263. doi:10.3389/fonc.2020.01263
   PubMed Web of Science ®Google Scholar
• Boucard J, Linot C, Blondy T, et al. Small molecule-based fluorescent organic nanoassemblies with strong hydrogen bonding networks for fine tuning and monitoring drug delivery in cancer cells. Small. 2018;14:1802307. doi:10.1002/smll.201802307
   Web of Science ®Google Scholar
• Prantner AM, Turini M, Kerfelec B, et al. Anti-mesothelin nanobodies for both conventional and nanoparticle-based biomedical applications. J Biomed Nanotechnol. 2015;11:1201–1212. doi:10.1166/jbn.2015.2063
   PubMed Web of Science ®Google Scholar
• Faucon A, Maldiney T, Clément O, et al. Highly cohesive dual nanoassemblies for complementary multiscale bioimaging. J Mater Chem B. 2014;2:7747–7755. doi:10.1039/C4TB01199F
   PubMed Web of Science ®Google Scholar
• Hill SA, Benito-Alifonso D, Davis SA, et al. Practical three-minute synthesis of acid-coated fluorescent carbon dots with tuneable core structure. Sci Rep. 2018;8:12234. doi:10.1038/s41598-018-29674-2
   PubMed Web of Science ®Google Scholar
• Gueugnon F, Leclercq S, Blanquart C, et al. Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am J Pathol. 2011;178:1033–1042. doi:10.1016/j.ajpath.2010.12.014
   PubMed Web of Science ®Google Scholar
• Quetel L, Meiller C, Assié J-B, et al. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol. 2020;14:1207–1223. doi:10.1002/1878-0261.12651
   PubMed Web of Science ®Google Scholar
• Blondy T, Poly J, Linot C, et al. Impact of RAFT chain transfer agents on the polymeric shell density of magneto-fluorescent nanoparticles and their cellular uptake. Nanoscale. 2022;14:5884–5898. doi:10.1039/D1NR06769A
   PubMed Web of Science ®Google Scholar
• Rennick JJ, Johnston APR, Parton RG. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat Nanotechnol. 2021;16:266–276. doi:10.1038/s41565-021-00858-8
   PubMed Web of Science ®Google Scholar
• Rodríguez F, Caruana P, De la Fuente N, et al. Nano-based approved pharmaceuticals for cancer treatment: present and future challenges. Biomolecules. 2022;12:784. doi:10.3390/biom12060784
   PubMed Web of Science ®Google Scholar
• Pearce AK, O’Reilly RK. Insights into active targeting of nanoparticles in drug delivery: advances in clinical studies and design considerations for cancer nanomedicine. Bioconjug Chem. 2019;30:2300–2311. doi:10.1021/acs.bioconjchem.9b00456
   PubMed Web of Science ®Google Scholar
• Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019;71:1185–1198. doi:10.1111/jphp.13098
   PubMed Web of Science ®Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138–157. doi:10.1016/j.jconrel.2014.12.030
   PubMed Web of Science ®Google Scholar
• Saei AA, Yazdani M, Lohse SE, et al. Nanoparticle surface functionality dictates cellular and systemic toxicity. Chem Mater. 2017;29:6578–6595. doi:10.1021/acs.chemmater.7b01979
   Web of Science ®Google Scholar
• Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9:1410. doi:10.1038/s41467-018-03705-y
   PubMed Web of Science ®Google Scholar
• Bahrami B, Hojjat-Farsangi M, Mohammadi H, et al. Nanoparticles and targeted drug delivery in cancer therapy. Immunol Lett. 2017;190:64–83. doi:10.1016/j.imlet.2017.07.015
   PubMed Web of Science ®Google Scholar
• Verhaar ER, Woodham AW, Ploegh HL. Nanobodies in cancer. Semin Immunol. 2021;52:101425. doi:10.1016/j.smim.2020.101425
   PubMed Web of Science ®Google Scholar
• Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol. 2017;8:1603. doi:10.3389/fimmu.2017.01603
   PubMed Web of Science ®Google Scholar
• Chanier T, Chames P. Nanobody engineering: toward next generation immunotherapies and immunoimaging of cancer. Antibodies Basel Switz. 2019;8:1.
   Google Scholar
• Hu Y, Liu C, Muyldermans S. Nanobody-based delivery systems for diagnosis and targeted tumor therapy. Front Immunol. 2017;8:1442. doi:10.3389/fimmu.2017.01442
   PubMed Web of Science ®Google Scholar
• Sun S, Ding Z, Yang X, et al. Nanobody: a small antibody with big implications for tumor therapeutic strategy. Int J Nanomed. 2021;16:2337–2356. doi:10.2147/IJN.S297631
   PubMed Web of Science ®Google Scholar
• Asaadi Y, Jouneghani FF, Janani S, Rahbarizadeh F. A comprehensive comparison between camelid nanobodies and single chain variable fragments. Biomark Res. 2021;9:87. doi:10.1186/s40364-021-00332-6
   PubMed Web of Science ®Google Scholar
• Rossotti MA, Bélanger K, Henry KA, Tanha J. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022;289:4304–4327. doi:10.1111/febs.15809
   PubMed Web of Science ®Google Scholar
• Jovčevska I, Muyldermans S. The therapeutic potential of nanobodies. Biodrugs. 2020;34:11–26. doi:10.1007/s40259-019-00392-z
   PubMed Web of Science ®Google Scholar
• Yameen B, Choi WI, Vilos C, et al. Insight into nanoparticle cellular uptake and intracellular targeting. J Control Release off J Control Release Soc. 2014;190:485–499. doi:10.1016/j.jconrel.2014.06.038
   PubMed Web of Science ®Google Scholar
• Donahue ND, Acar H, Wilhelm S. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv Drug Deliv Rev. 2019. doi:10.1016/j.addr.2019.04.008
   PubMed Web of Science ®Google Scholar
• Wang X, Qiu Y, Wang M, et al. Endocytosis and organelle targeting of nanomedicines in cancer therapy. Int J Nanomed. 2020;15:9447–9467. doi:10.2147/IJN.S274289
   PubMed Web of Science ®Google Scholar
• Boucard J, Briolay T, Blondy T, et al. Hybrid azo-fluorophore organic nanoparticles as emissive turn-on probes for cellular endocytosis. ACS Appl Mater Interfaces. 2019;11:32808–32814. doi:10.1021/acsami.9b12989
   PubMed Web of Science ®Google Scholar
• Bertoglio P, Aprile V, Ambrogi MC, Mussi A, Lucchi M. The role of intracavitary therapies in the treatment of malignant pleural mesothelioma. J Thorac Dis. 2018;10:S293–S297. doi:10.21037/jtd.2017.10.165
   PubMed Web of Science ®Google Scholar
• Linot C, Poly J, Boucard J, et al. PEGylated anionic magnetofluorescent nanoassemblies: impact of their interface structure on magnetic resonance imaging contrast and cellular uptake. ACS Appl Mater Interfaces. 2017;9:14242–14257. doi:10.1021/acsami.7b01737
   PubMed Web of Science ®Google Scholar